Monopar Announces Presentation Selected for 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting
Monopar Therapeutics (MNPR) has announced that its abstract on camsirubicin will be presented at the 2022 Connective Tissue Oncology Society Annual Meeting in Vancouver, Canada, from November 16-19, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Monopar Therapeutics (MNPR) has announced that its abstract on camsirubicin will be presented at the 2022 Connective Tissue Oncology Society Annual Meeting in Vancouver, Canada, from November 16-19, 2022. This presentation will reveal data from a Phase 1b clinical trial of camsirubicin in advanced soft tissue sarcoma patients, marking the first formal release of this data. The conference gathers leading sarcoma specialists globally, and Monopar aims to share insights derived from its dose-escalation study.
Positive
- Data on camsirubicin will be presented at a prestigious oncology meeting.
- Monopar aims to engage with leading sarcoma specialists.
Negative
- None.
Details
News Market Reaction – MNPR
The recorded move for MNPR in the trading session of this news was +4.02%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WILMETTE, Ill., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that its abstract on camsirubicin submitted to the 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting has been selected for a poster presentation. CTOS 2022, held in Vancouver, Canada, brings together the world’s leading sarcoma specialists. Monopar’s poster will be the first formal release of data from its ongoing Phase 1b open-label clinical trial of camsirubicin in advanced soft tissue sarcoma (ASTS) patients.
“We are looking forward to sharing data from our dose-escalating camsirubicin study with leading sarcoma specialists from around the world in a little over a month,” said Chandler Robinson, MD, Monopar’s Chief Executive Officer.
Meeting Details:
Event: Connective Tissue Oncology Society (CTOS) Annual Meeting Conference
Date: November 16-19, 2022
Location: Vancouver Convention Centre, Vancouver, BC, Canada
About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of Validive® for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for the treatment of advanced soft tissue sarcoma; a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19; and an early-stage camsirubicin analog, MNPR-202, for various cancers. For more information, visit: www.monopartx.com.
CONTACT:
Monopar Therapeutics Inc.
Investor Relations
Kim R. Tsuchimoto
Chief Financial Officer
Follow Monopar on social media for updates:
Twitter: @MonoparTx LinkedIn: Monopar Therapeutics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.